» Articles » PMID: 23682571

Glutamic Acid and Its Derivatives: Candidates for Rational Design of Anticancer Drugs

Overview
Journal Future Med Chem
Specialties Chemistry
Pharmacy
Date 2013 May 21
PMID 23682571
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Throughout the history of human civilizations, cancer has been a major health problem. Its treatment has been interesting but challenging to scientists. Glutamic acid and its derivative glutamine are known to play interesting roles in cancer genesis, hence, it was realized that structurally variant glutamic acid derivatives may be designed and developed and, might be having antagonistic effects on cancer. The present article describes the state-of-art of glutamic acid and its derivatives as anticancer agents. Attempts have been made to explore the effectivity of drug-delivery systems based on glutamic acid for the delivery of anticancer drugs. Moreover, efforts have also been made to discuss the mechanism of action of glutamic acid derivatives as anticancer agents, clinical applications of glutamic acid derivatives, as well as recent developments and future perspectives of glutamic acid drug development have also been discussed.

Citing Articles

Prognostic models of immune-related cell death and stress unveil mechanisms driving macrophage phenotypic evolution in colorectal cancer.

Liu H, Zhang C, Peng S, Yin Y, Xu Y, Wu S J Transl Med. 2025; 23(1):127.

PMID: 39875913 PMC: 11776142. DOI: 10.1186/s12967-025-06143-9.


Increased nerve density adversely affects outcome in colorectal cancer and denervation suppresses tumor growth.

Wang H, Huo R, He K, Li W, Gao Y, He W J Transl Med. 2025; 23(1):112.

PMID: 39849539 PMC: 11760110. DOI: 10.1186/s12967-025-06104-2.


Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression.

Zhou M, Zhou Z, Hu L, Chen S, Meng F, Chen J J Transl Med. 2025; 23(1):88.

PMID: 39838375 PMC: 11748271. DOI: 10.1186/s12967-025-06106-0.


Molecule interacting with CasL-2 enhances tumor progression and alters radiosensitivity in cervical cancer.

Teng Y, Zhao H, Xue G, Zhang G, Huang Y, Guo W J Transl Med. 2025; 23(1):44.

PMID: 39799334 PMC: 11725214. DOI: 10.1186/s12967-024-06065-y.


Multi-omics-driven discovery of invasive patterns and treatment strategies in CA19-9 positive intrahepatic cholangiocarcinoma.

Ma D, Wei P, Liu H, Hao J, Chen Z, Chu Y J Transl Med. 2024; 22(1):1031.

PMID: 39548460 PMC: 11568536. DOI: 10.1186/s12967-024-05854-9.